|
SRP9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.5267000000051E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.23000000000506E-05 |
| Normal-vs-Stage2 |
9.741900E-03 |
| Normal-vs-Stage3 |
6.33669999999809E-05 |
| Normal-vs-Stage4 |
2.08499999487799E-08 |
| Stage1-vs-Stage2 |
6.506000E-01 |
| Stage1-vs-Stage3 |
4.829200E-01 |
| Stage1-vs-Stage4 |
8.103800E-03 |
| Stage2-vs-Stage3 |
3.899600E-01 |
| Stage2-vs-Stage4 |
1.024270E-02 |
| Stage3-vs-Stage4 |
6.198300E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.44170000004884E-06 |
| Normal-vs-AfricanAmerican |
1.140840E-01 |
| Normal-vs-Asian |
2.42199999999082E-05 |
| Caucasian-vs-AfricanAmerican |
4.349200E-01 |
| Caucasian-vs-Asian |
7.095400E-01 |
| AfricanAmerican-vs-Asian |
4.247200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.95120000000238E-05 |
| Normal-vs-Female |
4.0163000000204E-06 |
| Male-vs-Female |
8.888400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.199420E-04 |
| Normal-vs-Age(41-60Yrs) |
3.48210000000737E-06 |
| Normal-vs-Age(61-80Yrs) |
1.244260E-03 |
| Normal-vs-Age(81-100Yrs) |
5.920200E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.651800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.627800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.034600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.109200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.816380E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.467000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.571800E-02 |
| Classical-VS-Follicular |
4.489000E-01 |
| Classical-VS-Other |
3.604400E-01 |
| Classical-VS-Normal |
3.447500E-04 |
| Tall-VS-Follicular |
1.862270E-02 |
| Tall-VS-Other |
8.287400E-01 |
| Tall-VS-Normal |
2.37349999998582E-06 |
| Follicular-VS-Other |
2.881000E-01 |
| Follicular-VS-Normal |
6.961200E-03 |
| Other-VS-Normal |
1.102460E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.75189999999904E-05 |
| Normal-vs-N1 |
1.40329999842592E-08 |
| N0-vs-N1 |
5.604900E-03 |
|
|
